GLI1 and skin basal cell carcinoma: When patients in the 2 dose groups were stratified by the type of BCC, median (95% CI) reduction in GLI1 expression at week 9 was 87.4% (55.6%–96.9%) and 94.2% (87.8%–98.4%) for patients with aggressive laBCC, 86.7% (80.8%–96.1%) and 97.2% (95.0%–98.9%) for patients with nonaggressive laBCC, and 98.2% (85.1%–98.5%) and 99.2% (94.3%–99.6%) for patients with mBCC receiving sonidegib 200 and 800 mg QD, respectively (Figure 1).